Pfizer Inc. (PFE)
Market Cap | 131.45B |
Revenue (ttm) | 62.46B |
Net Income (ttm) | 7.88B |
Shares Out | 5.69B |
EPS (ttm) | 1.38 |
PE Ratio | 16.71 |
Forward PE | 8.21 |
Dividend | $1.72 (7.44%) |
Ex-Dividend Date | May 9, 2025 |
Volume | 33,119,503 |
Open | 23.44 |
Previous Close | 23.39 |
Day's Range | 23.08 - 23.44 |
52-Week Range | 20.92 - 31.54 |
Beta | 0.49 |
Analysts | Hold |
Price Target | 29.92 (+29.41%) |
Earnings Date | Jul 29, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $29.92, which is an increase of 29.41% from the latest price.
News

These Stocks Are The High-Yield Dividend Investor's Best Friend
High-yield stocks are often riddled with flaws. However, there are some high-yield stocks available today that check all of my boxes. I share some of my top high-yield picks of the moment.

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Pfizer's R&D Optimization Delivers Great Results & Secure Dividends
PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outpe...

Buy, Sell, Or Hold PFE Stock At $23?
Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-...

June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035
My top 10 high-yield picks for June 2025 balance attractive dividend yields, strong financials, and competitive advantages to reduce risk and enhance returns. I use a rigorous four-step selection proc...

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Gold...
Pfizer (PFE) CEO on Braftovi Reducing Colorectal Cancer Death Risk "in Half"
Dr. Albert Bourla, CEO of Pfizer (PFE), joins Nicole Petallides on Morning Trade Live to discuss the latest results of his company's Braftovi drug trials. According to Dr. Bourla, results showed it ca...

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, according t...
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.

Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafe...

Collaborations for Change: AUA and Pfizer Select Recipients for $1.5 Million Grant Program to Improve Advanced Prostate Cancer Care
BALTIMORE, May 29, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is excited to announce it has selected seven grant winners to split $1.5 million as part of a collaborative initia...

Hearing Against Pfizer Set For 30 May In Contraceptive ‘Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio
PENSACOLA, Fla.--(BUSINESS WIRE)--A Case Management Conference (CMC) in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Friday, 30 May at 9:00am CT in the United States...

Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline
Despite recent underperformance, a "Buy" rating on Pfizer is reiterated due to a strong Q1 EPS beat, driven by significant cost controls and margin improvement, signaling operational strength. Managem...

Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immature...

Stocks With the Highest Dividend Yields in the S&P 500
Ford Motor and Dow lead the list of stocks with the highest dividend yields in the S&P 500. Some of the other names might surprise you.

Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatme...

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' May Dividend Dogs
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...

Pfizer Looks Like A Great Play At Current Valuations
Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, ...

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the g...
Pfizer Pacing for 4th Day of Gains
Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains.

Pfizer Thinks Bigger With 3SBio Deal
Pfizer Inc. decided to think bigger after the Summit deal in February and that it needs control of a PD-1/VEGF bispecific antibody versus participating with its ADC pipeline. The 3SBio deal allows inc...

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
Pfizer (PFE) has announced a new agreement to develop and market a cancer drug currently being developed by Chinese drugmaker 3SBio.
Pfizer strikes deal with China's 3SBio to license cancer drug
CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news.

Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug
Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug undergoing tr...